Population Of Retinal Ganglion Cells Research Articles

Asymmetric activation of ON and OFF pathways in degenerated retina.

Retinal prosthetics are one of the leading therapeutic strategies to restore lost vision in patients with Retinitis Pigmentosa and age-related macular degeneration. Much work has described patterns of spiking in retinal ganglion cells (RGCs) in response to electrical stimulation, but less work has examined the underlying retinal circuitry that is activated by electrical stimulation to drive these responses. Surprisingly, little is known about the role of inhibition in generating electrical responses, or how inhibition might be altered during degeneration. Using whole-cell voltage clamp recordings during subretinal electrical stimulation in rd10 and wt retina, we found electrically evoked synaptic inputs differed between ON and OFF RGC populations, with ON cells receiving mostly excitation and OFF cells receiving mostly inhibition and very little excitation. We found that inhibition of OFF bipolar cells limits excitation in OFF RGCs, and a majority of both pre and post synaptic inhibition in the OFF pathway arises from glycinergic amacrine cells, and stimulation of the ON pathway contributes to inhibitory inputs to the RGC. We also show that this presynaptic inhibition in the OFF pathway is greater in rd10 retina, compared to wild-type (wt) retina.Significance Statement Changes in circuit processing may have deleterious effects on vision restoration for patients with retinitis pigmentosa. Prior research has focused on feedforward excitatory drive and not the interactions between excitation and inhibition that comprise normal retinal function. This study demonstrates that retinal ganglion cells respond to electrical stimulation in three broad functional groups that correspond to their anatomical structure. We show that while both degenerated and wt retina display the same three groups, degenerated retina has an increased amount of OFF pathway presynaptic inhibition limiting their excitatory output to OFF ganglion cells.

POU6F2, a risk factor for glaucoma, myopia and dyslexia, labels specific populations of retinal ganglion cells

Pou6f2 is a genetic connection between central corneal thickness (CCT) in the mouse and a risk factor for developing primary open-angle glaucoma. POU6F2 is also a risk factor for several conditions in humans, including glaucoma, myopia, and dyslexia. Recent findings demonstrate that POU6F2-positive retinal ganglion cells (RGCs) comprise a number of RGC subtypes in the mouse, some of which also co-stain for Cdh6 and Hoxd10. These POU6F2-positive RGCs appear to be novel of ON–OFF directionally selective ganglion cells (ooDSGCs) that do not co-stain with CART or SATB2 (typical ooDSGCs markers). These POU6F2-positive cells are sensitive to damage caused by elevated intraocular pressure. In the DBA/2J mouse glaucoma model, heavily-labeled POU6F2 RGCs decrease by 73% at 8 months of age compared to only 22% loss of total RGCs (labeled with RBPMS). Additionally, Pou6f2−/− mice suffer a significant loss of acuity and spatial contrast sensitivity along with an 11.4% loss of total RGCs. In the rhesus macaque retina, POU6F2 labels the large parasol ganglion cells that form the magnocellular (M) pathway. The association of POU6F2 with the M-pathway may reveal in part its role in human glaucoma, myopia, and dyslexia.

Featured Cover

The cover image is based on the Original Article Rapid and efficient generation of a transplantable population of functional retinal ganglion cells from fibroblasts by Zihui Xu et al., https://doi.org/10.1111/cpr.13550. image

Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells.

Hereditary optic neuropathies (HONs) such as dominant optic atrophy (DOA) and Leber Hereditary Optic Neuropathy (LHON) are mitochondrial diseases characterized by a degenerative loss of retinal ganglion cells (RGCs) and are a cause of blindness worldwide. To date, there are only limited disease-modifying treatments for these disorders. The discovery of induced pluripotent stem cell (iPSC) technology has opened several promising opportunities in the field of HON research and the search for therapeutic approaches. This systematic review is focused on the two most frequent HONs (LHON and DOA) and on the recent studies related to the application of human iPSC technology in combination with biomaterials technology for their potential use in the development of RGC replacement therapies with the final aim of the improvement or even the restoration of the vision of HON patients. To this purpose, the combination of natural and synthetic biomaterials modified with peptides, neurotrophic factors, and other low- to medium-molecular weight compounds, mimicking the ocular extracellular matrices, with human iPSC or iPSC-derived cell retinal progenitors holds enormous potential to be exploited in the near future for the generation of transplantable RGC populations.

Idiosyncratic responses of RGCs to injury and protection

Objectives: The objectives of the study were to investigate the responses of different retinal ganglion cell (RGC) populations to diverse injuries [transient ischemia induced by acute ocular hypertension (AOH), excitotoxicity induced by intravitreal injection of 100 mM N‐methyl D‐aspartate (NMDA) or intra‐orbital optic nerve transection (IONT)] and protection with selective agonists of the tropomyosin related kinase B (TrkB) receptor, brain‐derived neurotrophic factor (BDNF) or 7,8‐Dihydroxyflavone (DHF) or with a voltage‐dependent calcium channel blocker (ITH12657).Methods: Adult Sprague–Dawley rats were used. In the first group, the left eye received a single intravitreal injection of 5 μL vehicle or 5 μg BDNF and was connected to a saline reservoir elevated above the eye to induce an acute ocular hypertension (AOH) and transient ischemia for 75 min. These rats were analysed at different survival intervals from 3 to 45 days.A second group were treated daily subcutaneously with vehicle or ITH5263 (10 mg/kg), or intraperitoneally with vehicle or DHF (5 mg/kg), starting 12 h prior to an intraocular injection of 100 mM N‐methyl‐D‐aspartate (NMDA) to induce retinal excitotoxicity. These rats were analysed at different survival intervals from 3 to 21 days.A third group received a left intra‐orbital optic nerve transection (IONT) to induce axotomy of the RGC population and were treated daily with an intraperitoneal injection of vehicle (0.9% NaCl containing 1% DMSO) or DHF (5 mg/kg diluted in vehicle). These rats were analysed at survival intervals from 3 to 60 days.The retinas were prepared as wholemounts and immunolabelled for Brn3a, melanopsin (m), Osteopontin (OPN) and the T‐box transcription factor T‐brain‐2 (Tbr2) to identify the following retinal ganglion cell populations: Brn3a+, melanopsin+, α‐like (OPN+), α‐ON sustained RGCs (OPN+Tbr2+), α‐ON transient RGCs (OPN+ Brn3a− Tbr2−) and α‐OFF like (OPN+Brn3a+). The labelled RGCs were quantified automatically (Brn3a) or dotted manually and quantified with a graphic software, and distribution of the different populations were represented on topographical maps.Results: Our studies document that:(i) AOH induces progressive loss of Brn3a+RGCs and a significant but not progressive loss of m+RGCs. Treatment with BDNF afforded significant long‐lasting protection for both RGC populations.(ii) Intravitreal injection of NMDA resulted at 7 days in the abrupt significant loss of Brn3a+RGCs, αRGC and αONs‐RGCs without further progression, whereas αOFF‐RGCs died massively. Both m+RGCs and αONtRGCs appear fully resistant to NMDA‐induced excitotoxicity. Both ITH12657 or DHF protect Brn3a+RGC, αRGCs and αONs‐RGCs, but not αOFF‐RGCs.(iii) IONT and vehicle treatment result in a characteristic rapid loss of Brn3a, melanopsin RGCs, αRGCs, αONs‐RGCs and αOFF‐RGCs. DHFs protect Brn3a + RGC, m + RGCs, αRGCs and αONs‐RGCs, but not αOFF‐RGCs.Conclusions: Thus, three different RGC populations (Brn3a+, m+ and α‐like) respond distinctly to different injuries and neuroprotective agents, further adding to the idea that each type of RGC has a unique response to injury and protection. Deciphering the molecular mechanisms of each RGC type will help understand neuronal responses to injury and its possible prevention.

Characterization of the whole Advillin expressing retinal ganglion cell population in the rodent retina

Aims/Purpose: We have quantified and examined the topography of the total population of retinal ganglion cells (RGC) expressing Advillin (Advillin+RGCs), an actin‐binding protein expressed in somatic sensory neurons, in the retinas, as well as their projections to the brain, in control adult Advillin‐Cretg/+ mice (Zurborg et al. Mol Pain 2011, 7:66).Methods: Retinas from adult Advillin‐Cretg/+ Ai14fl/fl C57BL/6J mice (Frutos‐Rincón et al., Int J Mol Sci 2022, 23:2997) expressing tdTomato were prepared as whole‐mounts, labelled with antibodies recognizing Brn3a and melanopsin. The entire Advillin+RGC population was quantified and its retinal distribution analysed by nearest neighbour maps. The brains were serial coronal crysectioned and the axonal Advillin+RGC projections in the brain were anatomically analysed.Results: Advillin protein was mainly located in the somas and axons of a subset of RGCs. Total number of Advillin+RGCs was 1947 ± 157 (mean ± SD; n = 7), which constitutes 5% of the total RGC population. Approximately 17.5% (340 ± 76) and 0% (3 ± 1) of the Advillin+RGC population co‐expressed Brn3a or melanopsin proteins, respectively. The Advillin+RGC population was distributed across the entire retina, with a higher concentration in the temporal region. The axons of this RGC subpopulation project to the main retinal recipient regions in the brain, such as the lateral geniculate nucleus (LGN) and superior colliculus (SC). However, none of these axons project to the suprachiasmatic nucleus. These data indicates that Advillin+RGCs is not a subpopulation of ipRGCs.Conclusions: The Advillin protein, which is characteristic of sensory neurons, is also expressed in a specific RGC subpopulation of the adult mouse retina. A small percentage of Advillin+RGCs expressed the Brn3a transcription factor, while none expressed melanopsin. The axons of Advillin+RGCs project to the typical retino‐recipient areas in the brain, excluding the suprachiasmatic nucleus.

Retinal ganglion cells in a mouse model of Alzheimer's disease: A temporal study

Aims/Purpose: Alzheimer's disease (AD) is a degenerative neurological disorder characterized by the progressive loss of neurons and their synapses in the brain. Similar alterations have been observed in the retina even before they manifest in the brain. The retina has been proposed as a readily accessible biomarker for AD. In a previous work utilizing a murine model of AD (APPNL‐F/NL‐F), changes in retinal thickness, as measured by optical coherence tomography (OCT), were observed at 15 and 17 months. The objective of this study was to quantitatively assess the population of retinal ganglion cells (RGCs) in this same AD murine model over a specified time period and compare it with wild‐type (WT) mice.Methods: To quantitatively assess the population of retinal ganglion cells we used two study groups: the APPNL‐F/NL‐F model throughout the time period of (6, 9, 12, 17, and 20 months) and compared with wild‐type (WT) mice age matched (n = 30 in both groups). The quantification of retinal ganglion cells (RGCs) was conducted using immunohistochemical analysis with the Brn3a marker. This analysis was performed using a semi‐automatic algorithm implemented in the MatLab environment, which was developed by the Ramón Castroviejo Institute for Ophthalmic Research. For the analysis, the entire retina was considered and segmented into the peripapillary, intermediate, and peripheral zones.Results: A statistically significant decresase (p < 0.05) in the population of Brn3a + cells was observed in the APPNL‐F/NL‐F group compared to the WT group. This decreased was found in the total retina at 12 months, in the peripapillary zone at 9, 12, and 20 months, and in the intermediate zone at 12 months of the study.Conclusions: The APPNL‐F/NL‐F mouse model exhibits RGCs loss at 9, 12, and 20 months, mirroring the patterns observed in human cases. These findings suggest that the model holds promise for investigating and studying mechanisms related to RGC degeneration in Alzheimer's disease.

The aged mouse retina: Anatomical and functional study of retinal ganglion cells

Aims/Purpose: the purpose of this work is to analyse anatomically and functionally the population of retinal ganglion cells (RGCs) throughout the mouse lifespan.Methods: Retinal functionality was studied by electroretinogram in male and female C57BL/6J mice at 3, 6 and 18 months of age. Retinas were dissected as flat mounts at 3 and 18 months, the total number of RGCs immunodetected with Brn3a and automatically quantified.Results: Regarding retinal functionality, we observed that the pSTR wave significantly decreased in males at 6 months (p < 0.01 vs. 3 months) and progressed significantly at 18 months (p < 0.01 vs. 6 months). In females, RGC functional decline was observed later than in males, at 18 months (p < 0.001 vs. 3 months). The loss of RGC functionality was not accompanied by RGC death, as the total number of RGCs remained constant in both sexes from 3 to 18 months of age.Conclusions: Aging of the retina is associated with functional changes that may be due to neuronal dysfunction rather than cell loss.

Electrical Input Filters of Ganglion Cells in Wild Type and Degenerating rd10 Mouse Retina as a Template for Selective Electrical Stimulation.

Bionic vision systems are currently limited by indiscriminate activation of all retinal ganglion cells (RGCs)- despite the dozens of known RGC types which each encode a different visual message. Here, we use spike-triggered averaging to explore how electrical responsiveness varies across RGC types toward the goal of using this variation to create type-selective electrical stimuli. A battery of visual stimuli and a randomly distributed sequence of electrical pulses were delivered to healthy and degenerating (4-week-old rd10) mouse retinas. Ganglion cell spike trains were recorded during stimulation using a 60-channel microelectrode array. Hierarchical clustering divided the recorded RGC populations according to their visual and electrical response patterns. Novel electrical stimuli were presented to assess type-specific selectivity. In healthy retinas, responses fell into 35 visual patterns and 14 electrical patterns. In degenerating retinas, responses fell into 12 visual and 23 electrical patterns. Few correspondences between electrical and visual response patterns were found except for the known correspondence of ON visual type with upward deflecting electrical type and OFF cells with downward electrical profiles. Further refinement of the approach presented here may yet yield the elusive nuances necessary for type-selective stimulation. This study greatly deepens our understanding of electrical input filters in the context of detailed visual response characterization and includes the most complete examination yet of degenerating electrical input filters.

Study of the single or combined action of three different neuroprotection strategies in an acute hypertension model in mice

Aims/Purpose: To study the neuroprotective effects of a TrkB receptor activator (DHF), a calcium channel blocker that prevents Ca2+ toxic influx (ITH12657) and/or a P2X7 receptor blocker (ITH15004) administered alone or in combination in an animal model of acute ocular hypertension (AOHT).Methods: Pigmented adult mice (C57BL/6 strain) were separated into 9 experimental groups (n = 8 per group), 7 received intraperitoneal injections of the neuroprotective drugs alone or in combination, 1 received saline as the vehicle group and 1 was naïve. AOHT was performed by connecting the anterior chamber of the left eye to a bottle of saline at a height of 130 cm achieving an intraocular pressure of 97 mmHg for 60 min. Longitudinally in vivo analysis of the pSTR amplitude and the inner retinal thickness was measured by electroretinogram and SD‐OCT, respectively; and ex vivo analysis of the retinal ganglion cell population was identified immunohistochemically by Brn3a at 7 after AOHT in all experimental groups.Results: The neuroprotectant treatment administered alone had a beneficial effect on the pSTR wave response amplitude (50–60% amplitude response) compared to vehicles (⁓25% amplitude response), which increased in all treatment combinations (⁓75%) except for ITH12657+ ITH15004 at 7 days after AOHT. Similar results were obtained in the inner retinal thickness, with the combined treatments producing a better retinal response after 7 days of AOHT, particularly for DHF + ITH15004 and DHF + ITH12657 + ITH15004 which showed no difference compared to control thicknesses. Regarding the RGC population, all treatments had a neuroprotective effect (⁓70% population survival at 7 days) compared to vehicles (⁓40%) which was not increased by their combination.Conclusions: The single or combined action of three different neuroprotective strategies results in functional and morphological protection of the retina 7 days after AOHT.

Multiple consecutive-biphasic pulse stimulation improves spatially localized firing of retinal ganglion cells in the degenerate retina.

Retinal prostheses have shown some clinical success in restoring vision in patients with retinitis pigmentosa. However, the post-implantation visual acuity does not exceed that of legal blindness. The reason for the poor visual acuity might be that (1) degenerate retinal ganglion cells (RGCs) are less responsive to electrical stimulation than normal RGCs, and (2) electrically-evoked RGC spikes show a more widespread not focal response. The single-biphasic pulse electrical stimulation, commonly used in artificial vision, has limitations in addressing these issues. In this study, we propose the benefit of multiple consecutive-biphasic pulse stimulation. We used C57BL/6J mice and C3H/HeJ (rd1) mice for the normal retina and retinal degeneration model. An 8 × 8 multi-electrode array was used to record electrically-evoked RGC spikes. We compared RGC responses when increasing the amplitude of a single biphasic pulse versus increasing the number of consecutive biphasic pulses at the same stimulus charge. Increasing the amplitude of a single biphasic pulse induced more RGC spike firing while the spatial resolution of RGC populations decreased. For multiple consecutive-biphasic pulse stimulation, RGC firing increased as the number of pulses increased, and the spatial resolution of RGC populations was well preserved even up to 5 pulses. Multiple consecutive-biphasic pulse stimulation using two or three pulses in degenerate retinas induced as much RGC spike firing as in normal retinas. These findings suggest that the newly proposed multiple consecutive-biphasic pulse stimulation can improve the visual acuity in prosthesis-implanted patients.

Rapid and efficient generation of a transplantable population of functional retinal ganglion cells from fibroblasts.

Glaucoma and other optic neuropathies lead to progressive and irreversible vision loss by damaging retinal ganglion cells (RGCs) and their axons. Cell replacement therapy is a potential promising treatment. However, current methods to obtain RGCs have inherent limitations, including time-consuming procedures, inefficient yields and complex protocols, which hinder their practical application. Here, we have developed a straightforward, rapid and efficient approach for directly inducing RGCs from mouse embryonic fibroblasts (MEFs) using a combination of triple transcription factors (TFs): ASCL1, BRN3B and PAX6 (ABP). We showed that on the 6th day following ABP induction, neurons with molecular characteristics of RGCs were observed, and more than 60% of induced neurons became iRGCs (induced retinal ganglion cells) in the end. Transplanted iRGCs had the ability to survive and appropriately integrate into the RGC layer of mouse retinal explants and N-methyl-D-aspartic acid (NMDA)-damaged retinas. Moreover, they exhibited electrophysiological properties typical of RGCs, and were able to regrow dendrites and axons and form synaptic connections with host retinal cells. Together, we have established a rapid and efficient approach to acquire functional RGCs for potential cell replacement therapy to treat glaucoma and other optic neuropathies.

Various Forms of Programmed Cell Death Are Concurrently Activated in the Population of Retinal Ganglion Cells after Ischemia and Reperfusion.

Retinal ischemia-reperfusion (IR)-which ultimately results in retinal ganglion cell (RGC) death-is a common cause of visual impairment and blindness worldwide. IR results in various types of programmed cell death (PCD), which are of particular importance since they can be prevented by inhibiting the activity of their corresponding signaling cascades. To study the PCD pathways in ischemic RGCs, we used a mouse model of retinal IR and a variety of approaches including RNA-seq analysis, knockout animals, and animals treated with an iron chelator. In our RNA-seq analysis, we utilized RGCs isolated from retinas 24 h after IR. In ischemic RGCs, we found increased expression of many genes that regulate apoptosis, necroptosis, pyroptosis, oxytosis/ferroptosis, and parthanatos. Our data indicate that genetic ablation of death receptors protects RGCs from IR. We showed that the signaling cascades regulating ferrous iron (Fe2+) metabolism undergo significant changes in ischemic RGCs, leading to retinal damage after IR. This data suggests that the activation of death receptors and increased Fe2+ production in ischemic RGCs promote the simultaneous activation of apoptosis, necroptosis, pyroptosis, oxytosis/ferroptosis, and parthanatos pathways. Thus, a therapy is needed that concurrently regulates the activity of the multiple PCD pathways to reduce RGC death after IR.

Do all retinal ganglion cells respond similarly to injury and protection?

AbstractObjectives: To investigate the responses of different retinal ganglion cell (RGC) populations to diverse injuries and protection with selective agonists of the tropomyosin related kinase B (TrkB) receptor, brain‐derived neurotrophic factor (BDNF) or 7,8‐dihydroxyflavone (DHF).Methods: Adult Sprague–Dawley rats were used. A first group had their left eye connected to a saline reservoir elevated 1.5 meters above the eye to produce an acute ocular hypertension (AOH) and induce transient ischemia for 75 minutes, these were analysed at 3, 7, 14 or 45 days (d) (n = 9–14 for each survival interval). A second group received an intraocular injection of 100 mM N‐methyl‐D‐aspartate (NMDA) to induce retinal excitotoxicity and was analysed at 3, 7, 14d or 15 months (n = 7–11 for each survival interval). A third group received a left intraorbital optic nerve transection (IONT) to induce axotomy of the RGC population, these were analysed at 7, 10, 14, 21, 30 or 60d (n = 8 for each survival interval). The first group of rats received right after AOH a single intravitreal injection of 5 μl vehicle (1% Albumin in PBS) or 5 μg BDNF. Rats of the third group were treated daily with an intraperitoneal injection of vehicle (0.9% NaCl containing 1% DMSO) or DHF (5 mg/kg diluted in vehicle), while rats of the second group were untreated. The retinas were prepared as wholemounts and immunolabelled with Brn3a and melanopsin (m) antibodies to identify Brn3a+RGCs and m+RGCs, respectively. Wholemount image reconstructions were photographed; labelled RGCs were quantified and their distribution evaluated with isodensity or neighbour maps.Results: AOH with vehicle treatment results in rapid progressive loss of Brn3a+RGCs and in significant but not progressive loss of m+RGCs; BDNF treatment afforded significant prevention which was long‐lasting for both RGC populations. Intravitreal NMDA resulted at 7d in the abrupt loss of 74% of the Brn3a+RGC population but it did not progress further. The m+RGC population showed a significant diminution by 3d that recovered to control values by 7d and did not vary thereafter. IONT with vehicle treatment resulted in typical losses of RGCs that by 14d amounted to 80% or 64% of the Brn3a+ or m+RGC population, respectively. Brn3a+RGCs further decreased up to 60d whereas m+RGCs did not, so that the proportion of surviving m+RGCs was ≈five times that of Brn3a+RGCs, further showing their resilience to IONT. Systemic administration of DHF prevented Brn3a+RGC losses up to 21d while for m+RGCs such prevention was permanent.Conclusions: Our studies document that: (i) AOH induces progressive loss of Brn3a+RGCs but not of m+RGCs, and both populations respond to TrkB‐mediated protection; (ii) NMDA induced excitotoxicity results in rapid loss of Brn3a+RGCs, whereas m+RGCs survived for up to 15 months later; (iii) IONT and vehicle treatment result in characteristic rapid loss of Brn3a and melanopsin RGCs, whereas DHF treatment affords protection of axotomized RGCs. This protection is maximal at 7d and significant until 21d for Brn3a+RGCs, whereas for m+RGCs the protection was significant at 14d and permanent. Thus, two different RGC populations (Brn3a+ and m+) respond distinctly to injury and TrkB‐mediated protection.

Systemic administration of 7,8‐dihydroxyflavone (DHF) after intraorbital optic nerve section in the rat produces neuroprotection of the Brn3a+retinal ganglion cell population

AbstractObjective: To investigate the short‐ and long‐term responses of different retinal ganglion cell (RGC) populations to intraorbital optic nerve transection (IONT) and their protection with systemic administration of 7,8‐dihydroxyflavone (DHF), a potent selective agonist of the tropomyosin related kinase B (TrkB) receptor,Methods: Adult anaesthetized Sprague–Dawley rats received an IONT of their left eye and daily intraperitoneal (ip) injections of vehicle (0.9% NaCl containing 1% DMSO) or of DHF (5 mg/kg in the same vehicle). One group of animals was used to investigate long term protection of DHF and was processed 7, 10, 14, 21, 30 or 60 days (n = 8 for each survival interval) after the lesion. Another group of animals was used to investigate the responses of different RGC types to DHF treatment and was processed 7, 14 or 21 days (n = 5–8 for each survival interval) after the lesion. The retinas were prepared as wholemounts and immunolabelled for Brn3a, melanopsin (m), Osteopontin (OPN) and the T‐box transcription factor T‐brain‐2 (Tbr2) to identify the following retinal ganglion cells (RGCs) populations: Brn3a+, melanopsin+, α‐ like (OPN+), α‐OFF like (OPN+Brn3a+) and M4‐like/α‐ON sustained RGCs (OPN+Tbr2+). The labelled RGCs were quantified automatically (Brn3a) or dotted manually and quantified with a graphic software, and distribution of the different populations represented on topographical logical maps.Results: IONT resulted in the loss of 83% or 59% of the Brn3a+ or m+RGC population, respectively, 14 days after vehicle treatment. The Brn3a+RGCs further diminished an additional 9% from 14 to 60 days whereas m+RGCs did not, thus at 60 days the proportion of surviving m+RGCs was almost five times greater than Brn3a+RGCs, thus showing greater resistance to IONT. Systemic administration of DHF resulted in prevention of Brn3a+RGCs loss during 21 days and permanent protection of m+RGCs. Different RGC populations showed different losses. In vehicle treated rats, IONT resulted in the rapid and massive loss of all OPN+Brn3a+RGCS, progressive and massive loss of Brn3a+RGCs and large but not progressive loss of OPN+RGCs or OPN+Tbr2+RGCs, indicating a certain resistance of the later types to IONT. DHF treatment resulted in significant prevention of the IONT‐induced loss of Brn3a+, OPN+ and OPN+‐Tbr2+ RGCs, but not of the OPN+‐Brn3a+.Conclusions: Our in vivo studies on adult rats document that IONT and vehicle treatment results in characteristic patterns of loss of the different types of RGCs including Brn3a, melanopsin, alpha and alpha‐ON sustained RGCs, although melanopsin, alpha and alpha‐ON sustained RGCs show certain resistance to the injury. DHF treatment affords in vivo protection of axotomized RGCs that lasts 21 days for the Brn3a+, m+, alpha and alpha‐ON sustained, but not for alpha‐OFF RGCs, which were not responsive to treatment.

Drug Discovery Strategies for Inherited Retinal Degenerations.

Simple SummaryInherited retinal degeneration is a group of heterogeneous genetic disorders impairing vision. In these diseases, photoreceptor or retinal ganglion cells become dysfunctional and degenerate. Currently, no cures exist for these devastating blinding conditions. In this review, we will discuss targets and drug discovery strategies for inherited retinal degeneration using animal models, stem cells, and small molecule screening with updates on preclinical developments.Inherited retinal degeneration is a group of blinding disorders afflicting more than 1 in 4000 worldwide. These disorders frequently cause the death of photoreceptor cells or retinal ganglion cells. In a subset of these disorders, photoreceptor cell death is a secondary consequence of retinal pigment epithelial cell dysfunction or degeneration. This manuscript reviews current efforts in identifying targets and developing small molecule-based therapies for these devastating neuronal degenerations, for which no cures exist. Photoreceptors and retinal ganglion cells are metabolically demanding owing to their unique structures and functional properties. Modulations of metabolic pathways, which are disrupted in most inherited retinal degenerations, serve as promising therapeutic strategies. In monogenic disorders, great insights were previously obtained regarding targets associated with the defective pathways, including phototransduction, visual cycle, and mitophagy. In addition to these target-based drug discoveries, we will discuss how phenotypic screening can be harnessed to discover beneficial molecules without prior knowledge of their mechanisms of action. Because of major anatomical and biological differences, it has frequently been challenging to model human inherited retinal degeneration conditions using small animals such as rodents. Recent advances in stem cell-based techniques are opening new avenues to obtain pure populations of human retinal ganglion cells and retinal organoids with photoreceptor cells. We will discuss concurrent ideas of utilizing stem-cell-based disease models for drug discovery and preclinical development.

Retinal Ganglion Cells: Global Number, Density and Vulnerability to Glaucomatous Injury in Common Laboratory Mice.

How many RBPMS+ retinal ganglion cells (RGCs) does a standard C57BL/6 laboratory mouse have on average and is this number substrain- or sex-dependent? Do RGCs of (European) C57BL/6J and -N mice show a different intrinsic vulnerability upon glaucomatous injury? Global RGC numbers and densities of common laboratory mice were previously determined via axon counts, retrograde tracing or BRN3A immunohistochemistry. Here, we report the global RGC number and density by exploiting the freely available tool RGCode to automatically count RGC numbers and densities on entire retinal wholemounts immunostained for the pan-RGC marker RBPMS. The intrinsic vulnerability of RGCs from different substrains to glaucomatous injury was evaluated upon introduction of the microbead occlusion model, followed by RBPMS counts, retrograde tracing and electroretinography five weeks post-injury. We demonstrate that the global RGC number and density varies between substrains, yet is not sex-dependent. C57BL/6J mice have on average 46K ± 2K RBPMS+ RGCs per retina, representing a global RGC density of 3268 ± 177 RGCs/mm2. C57BL/6N mice, on the other hand, have on average less RBPMS+ RGCs (41K ± 3K RGCs) and a lower density (3018 ± 189 RGCs/mm2). The vulnerability of the RGC population of the two C57BL/6 substrains to glaucomatous injury did, however, not differ in any of the interrogated parameters.

Single-cell transcriptome analysis of regenerating RGCs reveals potent glaucoma neural repair genes

Axon regeneration holds great promise for neural repair of CNS axonopathies, including glaucoma. Pten deletion in retinal ganglion cells (RGCs) promotes potent optic nerve regeneration, but only a small population of Pten-null RGCs are actually regenerating RGCs (regRGCs); most surviving RGCs (surRGCs) remain non-regenerative. Here, we developed a strategy to specifically label and purify regRGCs and surRGCs, respectively, from the same Pten-deletion mice after optic nerve crush, in which they differ only in their regeneration capability. Smart-Seq2 single-cell transcriptome analysis revealed novel regeneration-associated genes that significantly promote axon regeneration. The most potent of these, Anxa2, acts synergistically with its ligand tPA in Pten-deletion-induced axon regeneration. Anxa2, its downstream effector ILK, and Mpp1 dramatically protect RGC somata and axons and preserve visual function in a clinically relevant model of glaucoma, demonstrating the exciting potential of this innovative strategy to identify novel effective neural repair candidates.

How We See Black and White: The Role of Midget Ganglion Cells.

According to classical opponent color theory, hue sensations are mediated by spectrally opponent neurons that are excited by some wavelengths of light and inhibited by others, while black-and-white sensations are mediated by spectrally non-opponent neurons that respond with the same sign to all wavelengths. However, careful consideration of the morphology and physiology of spectrally opponent L vs. M midget retinal ganglion cells (RGCs) in the primate retina indicates that they are ideally suited to mediate black-and-white sensations and poorly suited to mediate color. Here we present a computational model that demonstrates how the cortex could use unsupervised learning to efficiently separate the signals from L vs. M midget RGCs into distinct signals for black and white based only correlation of activity over time. The model also reveals why it is unlikely that these same ganglion cells could simultaneously mediate our perception of red and green, and shows how, in theory, a separate small population of midget RGCs with input from S, M, and L cones would be ideally suited to mediating hue perception.

Artificial Visual Information Produced by Retinal Prostheses.

Numerous retinal prosthetic systems have demonstrated somewhat useful vision can be restored to individuals who had lost their sight due to outer retinal degenerative diseases. Earlier prosthetic studies have mostly focused on the confinement of electrical stimulation for improved spatial resolution and/or the biased stimulation of specific retinal ganglion cell (RGC) types for selective activation of retinal ON/OFF pathway for enhanced visual percepts. To better replicate normal vision, it would be also crucial to consider information transmission by spiking activities arising in the RGC population since an incredible amount of visual information is transferred from the eye to the brain. In previous studies, however, it has not been well explored how much artificial visual information is created in response to electrical stimuli delivered by microelectrodes. In the present work, we discuss the importance of the neural information for high-quality artificial vision. First, we summarize the previous literatures which have computed information transmission rates from spiking activities of RGCs in response to visual stimuli. Second, we exemplify a couple of studies which computed the neural information from electrically evoked responses. Third, we briefly introduce how information rates can be computed in the representative two ways – direct method and reconstruction method. Fourth, we introduce in silico approaches modeling artificial retinal neural networks to explore the relationship between amount of information and the spiking patterns. Lastly, we conclude our review with clinical implications to emphasize the necessity of considering visual information transmission for further improvement of retinal prosthetics.